Syros Pharmaceuticals Inc New Data From Phase 2 Clinical Trial of SY-1425 and Plans to Initiate Registration-Enabling Trial in MDS and Randomized Phase 2 Trial in AML Call Transcript
Good afternoon, and welcome to Syros Pharmaceuticals Conference call. (Operator Instructions) This call is being webcast live on the Investor & Media section of Syros webcast -- website at www.syros.com. Please be advised that today's call is being recorded. Following the formal remarks, we will open the call up for your questions. At this time, I would like to turn the call over to Naomi Aoki, Vice President of Corporate Communications and Investor Relations at Syros.
Thank you. Earlier today, we issued 2 press releases: one announcing clinical data for SY-1425, which are being presented this weekend at the ASH annual meeting; and the other announcing our acquisition from Orsenix of all of its assets related to a novel oral form of arsenic trioxide, which we are calling SY-2101, as well as the $90.5 million private placement. The releases along with the slides we'll be reviewing on today's call are available on the
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
